NASDAQ:ALLK - Allakos Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $197.67
  • Forecasted Upside: 113.05 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$92.78
▲ +0.92 (1.00%)

This chart shows the closing price for ALLK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Allakos Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALLK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALLK

Analyst Price Target is $197.67
▲ +113.05% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Allakos in the last 3 months. The average price target is $197.67, with a high forecast of $230.00 and a low forecast of $145.00. The average price target represents a 113.05% upside from the last price of $92.78.

This chart shows the closing price for ALLK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Allakos. This rating has held steady since December 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2021HC WainwrightInitiated CoverageBuy$230.00Low
2/24/2021Cantor FitzgeraldInitiated CoverageOverweight$218.00Low
1/15/2021Bank of AmericaInitiated CoverageBuy$145.00Low
12/21/2020SVB LeerinkInitiated CoverageOutperformHigh
10/22/2020Lifesci CapitalReiterated RatingOutperformLow
3/26/2020William BlairReiterated RatingBuyLow
2/27/2020BarclaysInitiated CoverageUnderweight$36.00High
2/4/2020The Goldman Sachs GroupReiterated RatingNeutral$94.00Low
8/9/2019William BlairReiterated RatingBuyLow
8/13/2018Jefferies Financial GroupInitiated CoverageBuy$53.00Low
8/13/2018William BlairInitiated CoverageOutperformLow
8/13/2018The Goldman Sachs GroupInitiated CoverageNeutral$31.00Low
(Data available from 6/21/2016 forward)
Allakos logo
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $92.78
Low: $91.80
High: $96.47

50 Day Range

MA: $100.21
Low: $89.26
High: $113.31

52 Week Range

Now: $92.78
Low: $66.01
High: $157.98

Volume

294,743 shs

Average Volume

248,794 shs

Market Capitalization

$4.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Allakos?

The following equities research analysts have issued stock ratings on Allakos in the last year: Bank of America Co., Cantor Fitzgerald, HC Wainwright, Lifesci Capital, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for ALLK.

What is the current price target for Allakos?

3 Wall Street analysts have set twelve-month price targets for Allakos in the last year. Their average twelve-month price target is $197.67, suggesting a possible upside of 105.7%. HC Wainwright has the highest price target set, predicting ALLK will reach $230.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $145.00 for Allakos in the next year.
View the latest price targets for ALLK.

What is the current consensus analyst rating for Allakos?

Allakos currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALLK will outperform the market and that investors should add to their positions of Allakos.
View the latest ratings for ALLK.

What other companies compete with Allakos?

How do I contact Allakos' investor relations team?

Allakos' physical mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company's listed phone number is 650-597-5002 and its investor relations email address is [email protected] The official website for Allakos is www.allakos.com.